For decades researchers have worked to find a way to orally administer insulin effectively to patients with diabetes. Now this game-changing treatment is one step closer to reality, with pharmaceutical company Oramed embarking on a final Phase 2b human clinical trial to prove the efficacy of its oral insulin before moving to the final stages of trials and registrations that could bring the treatment to market within a few short years.
Read the full article on newatlas.com
